Revenue (TTM) Chart

Historical Revenue (TTM) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 4.314M
March 31, 2026 7.063M
December 31, 2025 9.443M
September 30, 2025 11.65M
June 30, 2025 11.40M
March 31, 2025 11.20M
December 31, 2024 10.91M
September 30, 2024 10.26M
June 30, 2024 10.16M
March 31, 2024 9.812M
December 31, 2023 10.02M
September 30, 2023 10.21M
June 30, 2023 10.21M
March 31, 2023 10.40M
December 31, 2022 10.16M
September 30, 2022 10.41M
June 30, 2022 10.62M
March 31, 2022 10.52M
December 31, 2021 10.65M
September 30, 2021 10.54M
June 30, 2021 10.24M
March 31, 2021 10.32M
December 31, 2020 10.84M
September 30, 2020 11.10M
June 30, 2020 11.21M
Date Value
March 31, 2020 10.95M
December 31, 2019 10.00M
September 30, 2019 9.472M
June 30, 2019 9.463M
March 31, 2019 9.727M
December 31, 2018 10.43M
September 30, 2018 10.94M
June 30, 2018 10.53M
March 31, 2018 10.24M
December 31, 2017 9.898M
September 30, 2017 8.998M
June 30, 2017 8.313M
March 31, 2017 7.932M
December 31, 2016 7.527M
September 30, 2016 7.258M
June 30, 2016 7.544M
March 31, 2016 7.946M
December 31, 2015 7.878M
September 30, 2015 7.778M
June 30, 2015 7.498M
March 31, 2015 10.22M
December 31, 2014 9.844M
September 30, 2014 9.375M
June 30, 2014 14.81M
March 31, 2014 15.42M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (TTM) Range, Past 5 Years

View Revenue (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (TTM) Benchmarks

View Revenue (TTM) Benchmarks
Start Trial
Agenus, Inc. 132.69M
Amgen, Inc. 38.20B
BioCryst Pharmaceuticals, Inc. 940.61M
Imunon, Inc. 0.00
CEL-SCI Corp. 0.00